RevMed's pancreatic cancer drug Rasonque shows mixed results across KRAS subtypes, analysts stay optimistic

FDA review documents revealed that Revolution Medicines' newly approved pancreatic cancer therapy, Rasonque, performed unevenly in a large subgroup of patients. The data highlight a lower objective response rate for certain KRAS mutation types.

Across all KRAS mutations in the Phase 3 RASolute 302 trial, Rasonque achieved a 33% objective response rate. Patients with the G12V mutation (36% of participants) saw a 50% response, while those with G12D mutations (43% of participants) had a 24% response. The smallest cohort, patients with G12R mutations, recorded only a 7% response, which was below the response seen with standard chemotherapy.

The news prompted a more than 6% drop in RevMed's stock on the day of the release, but analysts described the market reaction as exaggerated. They continue to view the drug as a strong asset for the company, emphasizing the high response in the G12V subgroup and the overall potential of the RAS inhibitor platform.

RevMed noted that the G12R mutation represents a minor fraction of the pancreatic cancer population, suggesting the overall impact on the drug's market potential may be limited despite the subgroup's poor performance.